Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Z. DeFilipp, R. Ancheta, Y. Liu, Z.H. Hu, R.P. Gale, D. Snyder, H.C. Schouten, M. Kalaycio, G.C. Hildebrandt, C. Ustun, A. Daly, S. Ganguly, Y. Inamoto, M. Litzow, J. Szer, M.L. Savoie, N. Hossain, M.A. Kharfan-Dabaja, M. Hamadani, R. ReshefA. Bajel, K.R. Schultz, S. Gadalla, A. Gerds, J. Liesveld, M.B. Juckett, R. Kamble, S. Hashmi, H. Abdel-Azim, M. Solh, U. Bacher, H. Lazarus, R. Olsson, J.Y. Cahn, M.R. Grunwald, B.N. Savani, J. Yared, J.M. Rowe, J. Cerny, N.A. Chaudhri, M. Aljurf, A. Beitinjaneh, S. Seo, T. Nishihori, J.W. Hsu, M. Ramanathan, E. Alyea, U. Popat, R. Sobecks, W. Saber

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)472-479
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number3
DOIs
Publication statusPublished - 1 Mar 2020

Keywords

  • allogeneic hematopoietic cell transplantation
  • chronic myelogenous leukemia
  • chronic myeloid-leukemia
  • imatinib
  • maintenance
  • nilotinib prophylaxis
  • outcomes
  • therapy
  • tyrosine kinase inhibitor
  • NILOTINIB PROPHYLAXIS
  • Tyrosine kinase inhibitor
  • Chronic myelogenous leukemia
  • Maintenance
  • CHRONIC MYELOID-LEUKEMIA
  • THERAPY
  • Allogeneic hematopoietic cell transplantation
  • IMATINIB
  • OUTCOMES

Cite this